Piper Sandler analyst David Amsellem upgraded Teva Pharmaceutical to Neutral from Underweight with a price target of $12, up from $8.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TEVA:
- Corcept (NASDAQ:CORT) Faces Setback in Patent Case; Shares Decline
- HSBC Sees Opportunity in These 2 Biopharma Giants Ahead of the 2024 Elections
- Biogen: EC revokes centralized marketing authorizations for TECFIDERA generics
- Teva initiated with a Buy at HSBC
- Teva, Biolojic in pact for developing therapeutic antibodies for inflamation